Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Mar;38(3):465–472. doi: 10.1128/aac.38.3.465

A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

W V Kern 1, B Hay 1, P Kern 1, R Marre 1, R Arnold 1
PMCID: PMC284481  PMID: 8203838

Abstract

Fluoroquinolone prophylaxis in patients with profound neutropenia may be useful for preventing gram-negative bacterial infection, but it is ineffective against gram-positive bacterial infections in the bloodstream, particularly those caused by streptococci and coagulase-negative staphylococci, which appear to have emerged as significant causes of morbidity, decreased treatment efficacy, and the increased costs of empiric antimicrobial therapy. In a prospective, randomized, open trial, we evaluated the efficacy and safety of oral roxithromycin (150 mg twice daily) as additional antibacterial prophylaxis in 131 adult patients with acute leukemia and bone marrow transplant recipients receiving oral ofloxacin. In comparison with patients given ofloxacin alone, fewer patients receiving ofloxacin plus roxithromycin developed bacteremia caused by viridans group streptococci (incidence, 9 versus 0%; P = 0.03), while the incidence of bacteremia caused by other organisms, the incidence of febrile episodes from any cause, the risk of infection-associated complications (including prolonged or secondary fever, pneumonia, septic shock, need for mechanical ventilation, and/or infection-related death), and antimicrobial usage for therapy were comparable between both groups. Adverse events possibly related to the study drugs were slightly more common among the patients receiving the combination treatment (P = 0.05). Although effective for the prevention of streptococcal bacteremia, the addition of roxithromycin to a fluoroquinolone should not be used routinely as a prophylactic regimen in patients with profound neutropenia, but it might be considered and may be useful for cancer patients with a particularly high risk of streptococcal infection and related complications.

Full text

PDF
465

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attal M., Schlaifer D., Rubie H., Huguet F., Charlet J. P., Bloom E., Lemozy J., Massip P., Pris J., Laurent G. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. J Clin Oncol. 1991 May;9(5):865–870. doi: 10.1200/JCO.1991.9.5.865. [DOI] [PubMed] [Google Scholar]
  2. Awada A., van der Auwera P., Meunier F., Daneau D., Klastersky J. Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis. 1992 Jul;15(1):33–48. doi: 10.1093/clinids/15.1.33. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Jones R. N., Thornsberry C. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother. 1988 May;32(5):752–754. doi: 10.1128/aac.32.5.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bergogne-Bérézin E. Tissue distribution of roxithromycin. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):113–120. doi: 10.1093/jac/20.suppl_b.113. [DOI] [PubMed] [Google Scholar]
  5. Billaud E. M., Guillemain R., Fortineau N., Kitzis M. D., Dreyfus G., Amrein C., Kreft-Jaïs C., Husson J. M., Chrétien P. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet. 1990 Dec;19(6):499–502. doi: 10.2165/00003088-199019060-00006. [DOI] [PubMed] [Google Scholar]
  6. Bostrom B., Weisdorf D. Mucositis and alpha-streptococcal sepsis in bone marrow transplant recipients. Lancet. 1984 May 19;1(8386):1120–1121. doi: 10.1016/s0140-6736(84)92530-3. [DOI] [PubMed] [Google Scholar]
  7. Bow E. J., Rayner E., Louie T. J. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med. 1988 May;84(5):847–854. doi: 10.1016/0002-9343(88)90062-9. [DOI] [PubMed] [Google Scholar]
  8. Brook I., Ledney G. D. Ofloxacin and penicillin G combination therapy in prevention of bacterial translocation and animal mortality after irradiation. Antimicrob Agents Chemother. 1991 Aug;35(8):1685–1687. doi: 10.1128/aac.35.8.1685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brown A. E. Neutropenia, fever, and infection. Am J Med. 1984 Mar;76(3):421–428. doi: 10.1016/0002-9343(84)90661-2. [DOI] [PubMed] [Google Scholar]
  10. Burden A. D., Oppenheim B. A., Crowther D., Howell A., Morgenstern G. R., Scarffe J. H., Thatcher N. Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. Eur J Cancer. 1991;27(4):409–411. doi: 10.1016/0277-5379(91)90373-l. [DOI] [PubMed] [Google Scholar]
  11. Chantot J. F., Bryskier A., Gasc J. C. Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) 1986 May;39(5):660–668. doi: 10.7164/antibiotics.39.660. [DOI] [PubMed] [Google Scholar]
  12. Classen D. C., Burke J. P., Ford C. D., Evershed S., Aloia M. R., Wilfahrt J. K., Elliott J. A. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med. 1990 Oct;89(4):441–446. doi: 10.1016/0002-9343(90)90373-l. [DOI] [PubMed] [Google Scholar]
  13. Cohen J., Donnelly J. P., Worsley A. M., Catovsky D., Goldman J. M., Galton D. A. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet. 1983 Dec 24;2(8365-66):1452–1454. doi: 10.1016/s0140-6736(83)90799-7. [DOI] [PubMed] [Google Scholar]
  14. De Pauw B. E., Donnelly J. P., De Witte T., Nováková I. R., Schattenberg A. Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1990 Mar;5(3):179–182. [PubMed] [Google Scholar]
  15. Dekker A. W., Rozenberg-Arska M., Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987 Jan;106(1):7–11. doi: 10.7326/0003-4819-106-1-7. [DOI] [PubMed] [Google Scholar]
  16. Devaux Y., Archimbaud E., Guyotat D., Plotton C., Maupas J., Fleurette J., Fiere D. Streptococcal bacteremia in neutropenic adult patients. Nouv Rev Fr Hematol. 1992;34(2):191–195. [PubMed] [Google Scholar]
  17. Donnelly J. P., Maschmeyer G., Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer. 1992;28A(4-5):873–878. doi: 10.1016/0959-8049(92)90138-r. [DOI] [PubMed] [Google Scholar]
  18. Donnelly J. P., Muus P., Horrevorts A. M., Sauerwein R. W., De Pauw B. E. Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. Scand J Infect Dis. 1993;25(1):43–50. doi: 10.1080/00365549309169668. [DOI] [PubMed] [Google Scholar]
  19. Dybedal I., Lamvik J. Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans. Eur J Haematol. 1989 Apr;42(4):405–406. [PubMed] [Google Scholar]
  20. Elting L. S., Bodey G. P., Keefe B. H. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992 Jun;14(6):1201–1207. doi: 10.1093/clinids/14.6.1201. [DOI] [PubMed] [Google Scholar]
  21. Fanci R., Leoni F., Bosi A., Guidi S., Ciolli S., Longo G., Donnini E., Rossi Ferrini P. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin vs ciprofloxacin plus amoxicillin. J Chemother. 1993 Apr;5(2):119–123. doi: 10.1080/1120009x.1993.11739219. [DOI] [PubMed] [Google Scholar]
  22. Goldfarb J., Wormser G. P., Glaser J. H. Meningitis caused by multiply antibiotic-resistant viridans streptococci. J Pediatr. 1984 Dec;105(6):891–895. doi: 10.1016/s0022-3476(84)80072-4. [DOI] [PubMed] [Google Scholar]
  23. Groot-Loonen J. J., van der Noordaa J., de Kraker J., Voûte P. A., van Leeuwen E. F., Terpstra W. J., Ansink-Schipper M. C. Alpha-hemolytic streptococcal septicemia with severe complications during neutropenia in childhood cancer. Pediatr Hematol Oncol. 1987;4(4):323–328. doi: 10.3109/08880018709141285. [DOI] [PubMed] [Google Scholar]
  24. Guiot H. F., Peters W. G., van den Broek P. J., van der Meer J. W., Kramps J. A., Willemze R., van Furth R. Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection. 1990 May-Jun;18(3):131–137. doi: 10.1007/BF01642100. [DOI] [PubMed] [Google Scholar]
  25. Guiot H. F., van der Meer J. W., van den Broek P. J., Willemze R., van Furth R. Prevention of viridans-group streptococcal septicemia in oncohematologic patients: a controlled comparative study on the effect of penicillin G and cotrimoxazole. Ann Hematol. 1992 Jun;64(6):260–265. doi: 10.1007/BF01695467. [DOI] [PubMed] [Google Scholar]
  26. Hara K., Suyama N., Yamaguchi K., Kohno S., Saito A. Activity of macrolides against organisms responsible for respiratory infection with emphasis on Mycoplasma and Legionella. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):75–80. doi: 10.1093/jac/20.suppl_b.75. [DOI] [PubMed] [Google Scholar]
  27. Henslee J., Bostrom B., Weisdorf D., Ramsay N., McGlave P., Kersey J. Streptococcal sepsis in bone marrow transplant patients. Lancet. 1984 Feb 18;1(8373):393–393. doi: 10.1016/s0140-6736(84)90440-9. [DOI] [PubMed] [Google Scholar]
  28. Kern W., Kurrle E. Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection. 1991 Mar-Apr;19(2):73–80. doi: 10.1007/BF01645571. [DOI] [PubMed] [Google Scholar]
  29. Kern W., Kurrle E., Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection. 1990 May-Jun;18(3):138–145. doi: 10.1007/BF01642101. [DOI] [PubMed] [Google Scholar]
  30. Kern W., Kurrle E., Vanek E. High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia. Klin Wochenschr. 1987 Aug 17;65(16):773–780. doi: 10.1007/BF01743253. [DOI] [PubMed] [Google Scholar]
  31. Kern W., Linzmeier K., Kurrle E. Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection. 1989 Nov-Dec;17(6):396–397. doi: 10.1007/BF01645556. [DOI] [PubMed] [Google Scholar]
  32. Kotilainen P., Nikoskelainen J., Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis. 1990 Jan;161(1):41–44. doi: 10.1093/infdis/161.1.41. [DOI] [PubMed] [Google Scholar]
  33. Langley J., Gold R. Sepsis in febrile neutropenic children with cancer. Pediatr Infect Dis J. 1988 Jan;7(1):34–37. doi: 10.1097/00006454-198801000-00008. [DOI] [PubMed] [Google Scholar]
  34. Leblanc T., Leverger G., Arlet G., Siguret V., Schaison G. Fréquence et gravité des infections systémiques à streptocoques mitis et sanguis II chez les enfants neutropéniques. Pathol Biol (Paris) 1989 May;37(5):459–464. [PubMed] [Google Scholar]
  35. Lew M. A., Kehoe K., Ritz J., Antman K. H., Nadler L., Takvorian T., Mayer R., Kalish L., Finberg R. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar;51(3):630–636. doi: 10.1097/00007890-199103000-00017. [DOI] [PubMed] [Google Scholar]
  36. Liang R. H., Yung R. W., Chan T. K., Chau P. Y., Lam W. K., So S. Y., Todd D. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990 Feb;34(2):215–218. doi: 10.1128/aac.34.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mascret B., Maraninchi D., Gastaut J. A., Novakovitch G., Sebahoun G., Meyer G., Carcassonne Y. Risk factors for streptococcal septicaemia after marrow transplantation. Lancet. 1984 May 26;1(8387):1185–1186. doi: 10.1016/s0140-6736(84)91434-x. [DOI] [PubMed] [Google Scholar]
  38. McWhinney P. H., Gillespie S. H., Kibbler C. C., Hoffbrand A. V., Prentice H. G. Streptococcus mitis and ARDS in neutropenic patients. Lancet. 1991 Feb 16;337(8738):429–429. doi: 10.1016/0140-6736(91)91205-9. [DOI] [PubMed] [Google Scholar]
  39. McWhinney P. H., Patel S., Whiley R. A., Hardie J. M., Gillespie S. H., Kibbler C. C. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother. 1993 Nov;37(11):2493–2495. doi: 10.1128/aac.37.11.2493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Menichetti F., Del Favero A., Guerciolini R., Tonato M., Frongillo R. F., Roila F., Pauluzzi S. Viridans streptococci septicemia in cancer patients: a clinical study. Eur J Epidemiol. 1987 Sep;3(3):316–318. doi: 10.1007/BF00149743. [DOI] [PubMed] [Google Scholar]
  41. Menichetti F., Felicini R., Bucaneve G., Aversa F., Greco M., Pasquarella C., Moretti M. V., Del Favero A., Martelli M. F. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1989 Sep;4(5):489–492. [PubMed] [Google Scholar]
  42. Morávek J., Matousovic K., Prát V., Sedivý J. Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1990 Jun;28(6):262–267. [PubMed] [Google Scholar]
  43. Nilsen O. G., Aamo T., Zahlsen K., Svarva P. Macrolide pharmacokinetics and dose scheduling of roxithromycin. Diagn Microbiol Infect Dis. 1992 May-Jun;15(4 Suppl):71S–76S. doi: 10.1016/0732-8893(92)90130-l. [DOI] [PubMed] [Google Scholar]
  44. Ognibene F. P., Martin S. E., Parker M. M., Schlesinger T., Roach P., Burch C., Shelhamer J. H., Parrillo J. E. Adult respiratory distress syndrome in patients with severe neutropenia. N Engl J Med. 1986 Aug 28;315(9):547–551. doi: 10.1056/NEJM198608283150904. [DOI] [PubMed] [Google Scholar]
  45. Oppenheim B. A., Hartley J. W., Lee W., Burnie J. P. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. BMJ. 1989 Jul 29;299(6694):294–297. doi: 10.1136/bmj.299.6694.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Pechére J. C., Auckenthaler R. In-vitro activity of roxithromycin against respiratory and skin pathogens. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):1–5. doi: 10.1093/jac/20.suppl_b.1. [DOI] [PubMed] [Google Scholar]
  47. Pecquet S., Chachaty E., Tancrède C., Andremont A. Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrob Agents Chemother. 1991 Mar;35(3):548–552. doi: 10.1128/aac.35.3.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Potgieter E., Carmichael M., Koornhof H. J., Chalkley L. J. In vitro antimicrobial susceptibility of viridans streptococci isolated from blood cultures. Eur J Clin Microbiol Infect Dis. 1992 Jun;11(6):543–546. doi: 10.1007/BF01960811. [DOI] [PubMed] [Google Scholar]
  49. Quinn J. P., DiVincenzo C. A., Lucks D. A., Luskin R. L., Shatzer K. L., Lerner S. A. Serious infections due to penicillin-resistant strains of viridans streptococci with altered penicillin-binding proteins. J Infect Dis. 1988 Apr;157(4):764–769. doi: 10.1093/infdis/157.4.764. [DOI] [PubMed] [Google Scholar]
  50. Ringdén O., Heimdahl A., Lönnqvist B., Malmborg A. S., Wilczek H. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet. 1984 Mar 31;1(8379):744–744. doi: 10.1016/s0140-6736(84)92259-1. [DOI] [PubMed] [Google Scholar]
  51. Rozenberg-Arska M., Dekker A., Verdonck L., Verhoef J. Prevention of bacteremia caused by alpha-hemolytic streptococci by roxithromycin (RU-28 965) in granulocytopenic patients receiving ciprofloxacin. Infection. 1989 Jul-Aug;17(4):240–244. doi: 10.1007/BF01639528. [DOI] [PubMed] [Google Scholar]
  52. Santini C., Venditti M., Baiocchi P., Brandimarte C., Serra P., Mandelli F., Girmenia C., Micozzi A., Martino P. Emergence of penicillin-resistant viridans streptococci causing septicemia in granulocytopenic patients. Eur J Epidemiol. 1988 Sep;4(3):391–392. doi: 10.1007/BF00148932. [DOI] [PubMed] [Google Scholar]
  53. Schmeiser T., Kern W. V., Hay B., Hertenstein B., Arnold R. Single-drug oral antibacterial prophylaxis with ofloxacin in BMT recipients. Bone Marrow Transplant. 1993 Jul;12(1):57–63. [PubMed] [Google Scholar]
  54. Smith G. E., Fulford M. R., Matthews R. W., Speller D. C. Roxithromycin as a possible agent for prophylaxis of endocarditis: a study in normal volunteers. J Antimicrob Chemother. 1989 Mar;23(3):417–425. doi: 10.1093/jac/23.3.417. [DOI] [PubMed] [Google Scholar]
  55. Sotiropoulos S. V., Jackson M. A., Woods G. M., Hicks R. A., Cullen J., Freeman A. I. Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J. 1989 Nov;8(11):755–758. doi: 10.1097/00006454-198911000-00005. [DOI] [PubMed] [Google Scholar]
  56. Talbot G. H., Cassileth P. A., Paradiso L., Correa-Coronas R., Bond L. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother. 1993 Mar;37(3):474–482. doi: 10.1128/aac.37.3.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Valteau D., Hartmann O., Brugieres L., Vassal G., Benhamou E., Andremont A., Kalifa C., Lemerle J. Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy. Bone Marrow Transplant. 1991 Jun;7(6):415–419. [PubMed] [Google Scholar]
  58. Vansteenkiste J. F., Boogaerts M. A. Adult respiratory distress syndrome in neutropenic leukemia patients. Blut. 1989 Jun;58(6):287–290. doi: 10.1007/BF00320168. [DOI] [PubMed] [Google Scholar]
  59. Venditti M., Baiocchi P., Santini C., Brandimarte C., Serra P., Gentile G., Girmenia C., Martino P. Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients. Antimicrob Agents Chemother. 1989 Apr;33(4):580–582. doi: 10.1128/aac.33.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Venditti M., Santini C., Serra P., Micozzi A., Gentile G., Martino P. Comparative in vitro activities of new fluorinated quinolones and other antibiotics against coagulase-negative Staphylococcus blood isolates from neutropenic patients, and relationship between susceptibility and slime production. Antimicrob Agents Chemother. 1989 Feb;33(2):209–211. doi: 10.1128/aac.33.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Villablanca J. G., Steiner M., Kersey J., Ramsay N. K., Ferrieri P., Haake R., Weisdorf D. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant. 1990 Jun;5(6):387–393. [PubMed] [Google Scholar]
  62. Viscoli C., Van der Auwera P., Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother. 1988 Apr;21 (Suppl 100):149–156. doi: 10.1093/jac/21.suppl_c.149. [DOI] [PubMed] [Google Scholar]
  63. Weisman S. J., Scoopo F. J., Johnson G. M., Altman A. J., Quinn J. J. Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections. J Clin Oncol. 1990 Mar;8(3):453–459. doi: 10.1200/JCO.1990.8.3.453. [DOI] [PubMed] [Google Scholar]
  64. Wimperis J. Z., Baglin T. P., Marcus R. E., Warren R. E. An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant. 1991 Nov;8(5):363–367. [PubMed] [Google Scholar]
  65. Winston D. J., Ho W. G., Bruckner D. A., Gale R. P., Champlin R. E. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1990 Jan;88(1):36–42. doi: 10.1016/0002-9343(90)90125-w. [DOI] [PubMed] [Google Scholar]
  66. Winston D. J., Ho W. G., Nakao S. L., Gale R. P., Champlin R. E. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1986 May;80(5):884–890. doi: 10.1016/0002-9343(86)90633-9. [DOI] [PubMed] [Google Scholar]
  67. van der Lelie H., van Ketel R. J., von dem Borne A. E., van Oers R. H., Thomas B. L., Goudsmit R. Incidence and clinical epidemiology of streptococcal septicemia during treatment of acute myeloid leukemia. Scand J Infect Dis. 1991;23(2):163–168. doi: 10.3109/00365549109023395. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES